Aktis Reports Clinical Data for AKY-2519 at ASCO 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Clinical Data Presentation: Aktis Oncology showcased first-in-human imaging and dosimetry data for AKY-2519 at the 2026 ASCO Annual Meeting, revealing robust tumor uptake and limited normal tissue exposure in metastatic castration-resistant prostate cancer (mCRPC) patients, indicating a potentially differentiated profile in targeted radiopharmaceuticals.
- Trial Design Optimization: These findings informed the ongoing Phase 1b clinical trial design for AKY-2519, which is expected to initiate in the second half of 2026, demonstrating the company's strategic intent to expand clinical development opportunities across various B7-H3 expressing tumor types.
- Safety and Tolerability: The administration of AKY-2519 was generally well tolerated, with no adverse events or infusion-related reactions reported, establishing a solid safety profile that supports further clinical trial advancements.
- Tumor Absorbed Dose Assessment: Predicted absorbed doses of AKY-2519 in mCRPC patients showed favorable therapeutic ranges, particularly in the prostate and metastatic sites, suggesting its potential to address significant unmet medical needs in targeted therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTS
Wall Street analysts forecast AKTS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.120
Low
30.00
Averages
31.67
High
34.00
Current: 19.120
Low
30.00
Averages
31.67
High
34.00
About AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aktis Reports Clinical Data for AKY-2519 at ASCO 2026
- Clinical Data Presentation: Aktis Oncology showcased first-in-human imaging and dosimetry data for AKY-2519 at the 2026 ASCO Annual Meeting, revealing robust tumor uptake and limited normal tissue exposure in metastatic castration-resistant prostate cancer (mCRPC) patients, indicating a potentially differentiated profile in targeted radiopharmaceuticals.
- Trial Design Optimization: These findings informed the ongoing Phase 1b clinical trial design for AKY-2519, which is expected to initiate in the second half of 2026, demonstrating the company's strategic intent to expand clinical development opportunities across various B7-H3 expressing tumor types.
- Safety and Tolerability: The administration of AKY-2519 was generally well tolerated, with no adverse events or infusion-related reactions reported, establishing a solid safety profile that supports further clinical trial advancements.
- Tumor Absorbed Dose Assessment: Predicted absorbed doses of AKY-2519 in mCRPC patients showed favorable therapeutic ranges, particularly in the prostate and metastatic sites, suggesting its potential to address significant unmet medical needs in targeted therapies.
See More
Avidity Partners Acquires Stake in Aktis Oncology
- New Investment Position: Avidity Partners Management disclosed a new position in Aktis Oncology by acquiring 468,566 shares in Q1 2026, with an estimated transaction value of $9.10 million, indicating confidence in the company's future potential.
- Ownership Analysis: This acquisition represents 1.99% of Avidity's reportable AUM as of the quarter-end, highlighting its growing significance within the investment portfolio.
- Market Performance Review: As of May 12, 2026, Aktis Oncology shares were priced at $19.73, down approximately 27% from January's IPO highs but still above the $18 IPO price, reflecting cautious optimism about its future development.
- Financial Overview: Aktis Oncology has a market cap of $1 billion, with TTM revenue of $6.50 million and a net loss of $63.73 million; however, the company maintains a strong balance sheet with about $538.5 million in cash and marketable securities, expected to fund operations into 2029.
See More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion
- Acquisition Scale: UCB's announcement of acquiring Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront, signifies a major consolidation in the biopharmaceutical industry, expected to enhance UCB's market position in autoimmune and inflammatory disease treatments.
- Foundational Background: Candid was formed through the merger of Two River and Vignette Bio, with Two River playing a pivotal role in its founding and early development, showcasing its incubation capabilities and market influence in the biotechnology sector.
- Investment and Strategic Collaboration: Vida Ventures' investment in Candid reflects its strategy of supporting high-quality entrepreneurs, and Candid's successful trajectory illustrates the positive cycle of company creation and strategic collaboration within the Bellco ecosystem, further driving innovation.
- Future Growth Potential: Candid's focus on generating data in China through fast and cost-effective execution is expected to propel its treatment solutions to a global scale, with the collaborative model of Two River and Vida laying a solid foundation for the success of future biotechnology companies.
See More
Aktis Oncology Presents AKY-2519 Clinical Data at ASCO 2026
- Clinical Data Presentation: Aktis Oncology will present clinical imaging and dosimetry data for AKY-2519 at the 2026 American Society of Clinical Oncology Annual Meeting, which is expected to enhance understanding of B7-H3 expressing tumors and provide crucial insights for future treatment strategies.
- FDA Approval Progress: In March 2026, the FDA cleared the clinical trial application for AKY-2519, marking its entry into Phase 1b clinical trials, which are set to commence in mid-2026, thereby advancing its clinical development trajectory.
- Targeted Therapy Potential: As a miniprotein radioconjugate targeting B7-H3, AKY-2519 is designed for various solid tumors, including prostate and lung cancers, showcasing extensive potential in cancer treatment and the possibility of transforming existing therapeutic paradigms.
- International Collaborative Research: The clinical data acquisition involved collaboration between the University of Pretoria in South Africa and the University of Duisburg-Essen in Germany, utilizing PET/CT imaging to assess normal tissue and tumor uptake, thereby strengthening the capabilities of the international research network.
See More
Aktis Oncology Advances Targeted Radiopharmaceutical Development
- Clinical Trial Progress: Aktis Oncology announced FDA clearance of IND applications for AKY-2519, with plans to initiate a Phase 1b clinical trial in mid-2026, aimed at providing new treatment options for patients with various solid tumors such as prostate and lung cancer, thereby expanding the reach of targeted radiopharmaceuticals.
- Improved Financial Position: The company raised $365.4 million in gross proceeds from its IPO in 2025, significantly enhancing its cash flow and positioning it to fund operations into 2029, demonstrating strong performance in the capital markets.
- Increased R&D Investment: Research and development expenses reached $67.5 million in 2025, up from $41.0 million in 2024, primarily to support clinical studies for AKY-1189 and AKY-2519, indicating the company's commitment to advancing new drug development.
- Collaboration Revenue Growth: Collaboration revenue increased to $6.5 million in 2025 from $1.5 million in 2024, reflecting successful outcomes from the partnership with Eli Lilly, which enhances the company's market competitiveness and business expansion capabilities.
See More
Aktis Oncology Reports FY 2025 Financial Results
- Increased Net Loss: Aktis Oncology reported a net loss of $63.7 million for FY 2025, up from $44.0 million in 2024, primarily driven by rising R&D expenses, indicating ongoing investment and associated risks in drug development.
- Revenue Growth Challenges: Despite a 333.3% year-over-year revenue increase to $6.5 million, the figure fell short of expectations by $0.41 million, highlighting challenges in market acceptance and sales strategies.
- Cash Flow Status: As of December 31, 2025, the company held $226.8 million in cash and marketable securities, down from $297.2 million in 2024, reflecting pressures on financial management amid rising operational costs.
- Successful IPO Financing: Aktis Oncology completed its IPO in January 2026, generating approximately $335.3 million in net proceeds, resulting in a pro forma cash position of $562.1 million, which is expected to fund operations through 2029, thereby enhancing financial stability for future growth.
See More
Aktis Reports Clinical Data for AKY-2519 at ASCO 2026
- Clinical Data Presentation: Aktis Oncology showcased first-in-human imaging and dosimetry data for AKY-2519 at the 2026 ASCO Annual Meeting, revealing robust tumor uptake and limited normal tissue exposure in metastatic castration-resistant prostate cancer (mCRPC) patients, indicating a potentially differentiated profile in targeted radiopharmaceuticals.
- Trial Design Optimization: These findings informed the ongoing Phase 1b clinical trial design for AKY-2519, which is expected to initiate in the second half of 2026, demonstrating the company's strategic intent to expand clinical development opportunities across various B7-H3 expressing tumor types.
- Safety and Tolerability: The administration of AKY-2519 was generally well tolerated, with no adverse events or infusion-related reactions reported, establishing a solid safety profile that supports further clinical trial advancements.
- Tumor Absorbed Dose Assessment: Predicted absorbed doses of AKY-2519 in mCRPC patients showed favorable therapeutic ranges, particularly in the prostate and metastatic sites, suggesting its potential to address significant unmet medical needs in targeted therapies.
See More
Avidity Partners Acquires Stake in Aktis Oncology
- New Investment Position: Avidity Partners Management disclosed a new position in Aktis Oncology by acquiring 468,566 shares in Q1 2026, with an estimated transaction value of $9.10 million, indicating confidence in the company's future potential.
- Ownership Analysis: This acquisition represents 1.99% of Avidity's reportable AUM as of the quarter-end, highlighting its growing significance within the investment portfolio.
- Market Performance Review: As of May 12, 2026, Aktis Oncology shares were priced at $19.73, down approximately 27% from January's IPO highs but still above the $18 IPO price, reflecting cautious optimism about its future development.
- Financial Overview: Aktis Oncology has a market cap of $1 billion, with TTM revenue of $6.50 million and a net loss of $63.73 million; however, the company maintains a strong balance sheet with about $538.5 million in cash and marketable securities, expected to fund operations into 2029.
See More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion
- Acquisition Scale: UCB's announcement of acquiring Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront, signifies a major consolidation in the biopharmaceutical industry, expected to enhance UCB's market position in autoimmune and inflammatory disease treatments.
- Foundational Background: Candid was formed through the merger of Two River and Vignette Bio, with Two River playing a pivotal role in its founding and early development, showcasing its incubation capabilities and market influence in the biotechnology sector.
- Investment and Strategic Collaboration: Vida Ventures' investment in Candid reflects its strategy of supporting high-quality entrepreneurs, and Candid's successful trajectory illustrates the positive cycle of company creation and strategic collaboration within the Bellco ecosystem, further driving innovation.
- Future Growth Potential: Candid's focus on generating data in China through fast and cost-effective execution is expected to propel its treatment solutions to a global scale, with the collaborative model of Two River and Vida laying a solid foundation for the success of future biotechnology companies.
See More
Aktis Oncology Presents AKY-2519 Clinical Data at ASCO 2026
- Clinical Data Presentation: Aktis Oncology will present clinical imaging and dosimetry data for AKY-2519 at the 2026 American Society of Clinical Oncology Annual Meeting, which is expected to enhance understanding of B7-H3 expressing tumors and provide crucial insights for future treatment strategies.
- FDA Approval Progress: In March 2026, the FDA cleared the clinical trial application for AKY-2519, marking its entry into Phase 1b clinical trials, which are set to commence in mid-2026, thereby advancing its clinical development trajectory.
- Targeted Therapy Potential: As a miniprotein radioconjugate targeting B7-H3, AKY-2519 is designed for various solid tumors, including prostate and lung cancers, showcasing extensive potential in cancer treatment and the possibility of transforming existing therapeutic paradigms.
- International Collaborative Research: The clinical data acquisition involved collaboration between the University of Pretoria in South Africa and the University of Duisburg-Essen in Germany, utilizing PET/CT imaging to assess normal tissue and tumor uptake, thereby strengthening the capabilities of the international research network.
See More
Aktis Oncology Advances Targeted Radiopharmaceutical Development
- Clinical Trial Progress: Aktis Oncology announced FDA clearance of IND applications for AKY-2519, with plans to initiate a Phase 1b clinical trial in mid-2026, aimed at providing new treatment options for patients with various solid tumors such as prostate and lung cancer, thereby expanding the reach of targeted radiopharmaceuticals.
- Improved Financial Position: The company raised $365.4 million in gross proceeds from its IPO in 2025, significantly enhancing its cash flow and positioning it to fund operations into 2029, demonstrating strong performance in the capital markets.
- Increased R&D Investment: Research and development expenses reached $67.5 million in 2025, up from $41.0 million in 2024, primarily to support clinical studies for AKY-1189 and AKY-2519, indicating the company's commitment to advancing new drug development.
- Collaboration Revenue Growth: Collaboration revenue increased to $6.5 million in 2025 from $1.5 million in 2024, reflecting successful outcomes from the partnership with Eli Lilly, which enhances the company's market competitiveness and business expansion capabilities.
See More
Aktis Oncology Reports FY 2025 Financial Results
- Increased Net Loss: Aktis Oncology reported a net loss of $63.7 million for FY 2025, up from $44.0 million in 2024, primarily driven by rising R&D expenses, indicating ongoing investment and associated risks in drug development.
- Revenue Growth Challenges: Despite a 333.3% year-over-year revenue increase to $6.5 million, the figure fell short of expectations by $0.41 million, highlighting challenges in market acceptance and sales strategies.
- Cash Flow Status: As of December 31, 2025, the company held $226.8 million in cash and marketable securities, down from $297.2 million in 2024, reflecting pressures on financial management amid rising operational costs.
- Successful IPO Financing: Aktis Oncology completed its IPO in January 2026, generating approximately $335.3 million in net proceeds, resulting in a pro forma cash position of $562.1 million, which is expected to fund operations through 2029, thereby enhancing financial stability for future growth.
See More
